GO:0005138 interleukin-6 receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005138 (interleukin-6 receptor binding) is a molecular function describing the binding of a ligand to the interleukin-6 receptor (IL-6R).
• The primary ligand is the cytokine interleukin-6 (IL-6), which binds both membrane-bound and soluble forms of IL-6R.
• IL-6 binding to IL-6R triggers gp130 dimerization and downstream JAK/STAT3 signaling, a central pathway in inflammation and immunity.
• Dysregulated IL-6/IL-6R binding is implicated in autoimmune diseases, cytokine release syndrome, and cancers.
• Therapeutic blockade of IL-6R binding (e.g., tocilizumab) is clinically validated in rheumatoid arthritis and COVID-19.
• Research tools include RNA aptamers, CRISPR knockouts, and engineered cell models to dissect IL-6R binding specificity and signaling.
Description
Interleukin-6 receptor binding (GO:0005138) is a molecular function defined as the binding of a molecule to an interleukin-6 receptor (IL-6R). This function is critical for initiating signaling cascades that regulate immune responses, hematopoiesis, and acute-phase reactions. The primary ligand for IL-6R is the cytokine interleukin-6 (IL-6), a pleiotropic protein with both pro- and anti-inflammatory properties. Understanding this binding event is fundamental to immunology and drug development, as it represents a key node for therapeutic intervention in inflammatory diseases and cancer. Researchers study IL-6R binding to elucidate mechanisms of cytokine signaling, identify novel inhibitors, and model disease-associated mutations.
interleukin-6 receptor binding At A Glance
| GO ID | GO:0005138 |
|---|---|
| GO term | interleukin-6 receptor binding |
| Ontology | molecular_function |
| Synonym | IL-6, interleukin-6 receptor ligand |
| Major function | Binding to interleukin-6 receptor to initiate signaling |
| Ligand | Interleukin-6 (IL-6) and possibly other cytokines |
| Receptor | Interleukin-6 receptor (IL-6R, CD126) |
| Downstream effect | gp130 dimerization and JAK/STAT activation |
What Is GO:0005138?
According to the Gene Ontology, GO:0005138 (interleukin-6 receptor binding) is the molecular function of selectively interacting with and binding to an interleukin-6 receptor. This term encompasses the binding of IL-6 or other ligands to either the membrane-bound or soluble form of the IL-6 receptor, a prerequisite for receptor activation and signal transduction.
Why Is interleukin-6 receptor binding Important in Cell Biology?
Interleukin-6 receptor binding is a pivotal event in the initiation of IL-6 signaling, which controls diverse biological processes including inflammation, immune cell differentiation, and tissue regeneration. Dysregulation of this binding is directly linked to the pathogenesis of autoimmune diseases such as rheumatoid arthritis, as well as cytokine release syndrome and certain cancers. Moreover, therapeutic strategies that block IL-6R binding, such as monoclonal antibodies, have proven effective in treating these conditions, underscoring the clinical relevance of this molecular function.
• Initiates JAK/STAT3 signaling, a master regulator of inflammation and immunity.
• Central to the pathogenesis of rheumatoid arthritis and other autoimmune diseases.
• Mediates cytokine release syndrome in CAR-T therapy and severe COVID-19.
• Promotes tumor growth and survival in multiple myeloma and other cancers.
• Target of tocilizumab and sarilumab, FDA-approved IL-6R blockers.
• Involved in the acute-phase response and fever.
• Regulates B cell and T cell differentiation.
• Soluble IL-6R (sIL-6R) enables trans-signaling in cells lacking membrane IL-6R.
• Key research area for developing small-molecule inhibitors and aptamers.
• Essential for understanding cytokine storm and designing intervention strategies.
Molecular Mechanism of interleukin-6 receptor binding
Ligand Recognition and Binding
In simple terms: IL-6 grabs onto its receptor like a key in a lock.
Interleukin-6 (IL-6) binds with high affinity to the extracellular domain of the interleukin-6 receptor (IL-6R), a type I cytokine receptor. This binding is the first step in signal transduction and can occur on the cell membrane (classic signaling) or with a soluble form of IL-6R (trans-signaling). The interaction involves specific residues in IL-6 and the cytokine-binding homology region of IL-6R.
Receptor Complex Assembly
In simple terms: The receptor needs a partner to send the signal inside.
Upon IL-6 binding, the IL-6/IL-6R complex recruits two molecules of the signal-transducing receptor gp130 (IL6ST), forming a hexameric signaling complex. This assembly is essential for bringing the intracellular domains of gp130 into proximity, allowing activation of associated Janus kinases (JAKs).
JAK Activation and STAT3 Phosphorylation
In simple terms: JAK enzymes add phosphate tags to STAT3, turning it on.
The juxtaposed JAKs phosphorylate tyrosine residues on gp130, creating docking sites for STAT3. STAT3 is then phosphorylated, dimerizes, and translocates to the nucleus to regulate target gene expression. This pathway is a hallmark of IL-6 signaling and is often constitutively active in inflammatory diseases and cancers.
Regulation by Soluble Receptors and Trans-signaling
In simple terms: A soluble form of the receptor can spread the signal to cells that lack it.
Soluble IL-6R (sIL-6R), generated by proteolytic cleavage or alternative splicing, can bind IL-6 and stimulate cells that only express gp130, a process called trans-signaling. This expands the range of IL-6-responsive cells and is implicated in chronic inflammation.
Negative Feedback and Decay
In simple terms: The signal is shut off by inhibitors and receptor breakdown.
IL-6 signaling is tightly regulated by negative feedback loops, including SOCS proteins and phosphatases, which attenuate JAK/STAT activity. Receptor internalization and degradation also limit the duration of the signal.
Key Genes Involved in GO:0005138 interleukin-6 receptor binding
The following genes and proteins are central to interleukin-6 receptor binding and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL6 | Encodes interleukin-6, the primary ligand for IL-6R | Target for anti-inflammatory therapies; knockout models show impaired immune response |
| IL6R | Encodes the interleukin-6 receptor (CD126) | Mutations linked to autoimmune diseases; target of tocilizumab |
| IL6ST | Encodes gp130, the signal-transducing subunit | Essential for IL-6 signaling; mutations cause immunodeficiency |
| JAK1 | Janus kinase 1, phosphorylates gp130 and STATs | Inhibitors used in rheumatoid arthritis; knockout blocks IL-6 signaling |
| JAK2 | Janus kinase 2, alternative JAK for gp130 | Implicated in myeloproliferative neoplasms; research on signaling specificity |
| STAT3 | Signal transducer and activator of transcription 3 | Key downstream effector; constitutively active in many cancers |
| SOCS1 | Suppressor of cytokine signaling 1 | Negative regulator of IL-6 signaling; knockout leads to hyperinflammation |
| SOCS3 | Suppressor of cytokine signaling 3 | Feedback inhibitor of gp130 signaling |
| ADAM17 | Metalloprotease that cleaves membrane IL-6R to sIL-6R | Regulates trans-signaling; target for modulating inflammation |
| IL6R (soluble) | Soluble form of IL-6R generated by cleavage or splicing | Mediates trans-signaling; biomarker in inflammatory diseases |
| CRP | C-reactive protein, downstream acute-phase protein | Clinical marker of IL-6 activity |
| SAA1 | Serum amyloid A1, acute-phase protein | Induced by IL-6; marker of inflammation |
| FGG | Fibrinogen gamma chain, acute-phase protein | IL-6-regulated; involved in coagulation and inflammation |
| HAMP | Hepcidin, iron-regulatory hormone | Induced by IL-6; links inflammation to anemia |
| VEGFA | Vascular endothelial growth factor A | Induced by IL-6 in cancer; promotes angiogenesis |
| BCL2 | Anti-apoptotic protein | Upregulated by IL-6/STAT3 in myeloma |
| MYC | Oncogene transcription factor | Activated by IL-6 signaling in cancer |
| MMP9 | Matrix metalloproteinase 9 | Induced by IL-6; involved in tissue remodeling |
How Is interleukin-6 receptor binding Regulated?
Interleukin-6 receptor binding and signaling are regulated at multiple levels. Soluble gp130 can act as an antagonist by binding IL-6/sIL-6R complexes, thereby inhibiting trans-signaling. SOCS proteins provide negative feedback by inhibiting JAK activity. Additionally, proteolytic cleavage of membrane IL-6R by ADAM17 generates sIL-6R, which can either enhance or modulate signaling depending on context. Therapeutic agents such as tocilizumab block IL-6R binding directly.
interleukin-6 receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL6 | Rheumatoid arthritis, cytokine release syndrome | IL6 knockout mice; collagen-induced arthritis model |
| IL6R | Rheumatoid arthritis, COVID-19 | IL6R knockout cell lines; patient-derived PBMCs |
| STAT3 | Multiple myeloma, autoimmune diseases | STAT3 knockout or point-mutant cell lines |
| ADAM17 | Inflammatory diseases, cancer | ADAM17 knockout mice; cleavage-resistant IL6R knock-in |
| SOCS3 | Inflammation, cancer | SOCS3 knockout mice; overexpression cell models |
Autoimmune and Inflammatory Diseases
Dysregulated IL-6 receptor binding and signaling are central to the pathogenesis of rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease. Elevated IL-6 levels and sIL-6R contribute to chronic inflammation and joint destruction. Blocking IL-6R with tocilizumab has proven effective in these conditions.
Cytokine Release Syndrome and COVID-19
Severe COVID-19 and CAR-T-induced cytokine release syndrome are characterized by hyperactivation of IL-6 signaling. IL-6R blockade with tocilizumab reduces mortality in severe COVID-19 patients. This highlights the critical role of IL-6R binding in acute inflammatory crises.
Cancer
IL-6/IL-6R binding promotes tumor cell proliferation, survival, and angiogenesis, particularly in multiple myeloma, prostate cancer, and colorectal cancer. STAT3 activation downstream of IL-6R is a common oncogenic driver. Targeting IL-6R binding is a therapeutic strategy in these malignancies.
From interleukin-6 receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL6R knockout abolish IL-6 signaling? | IL6R knockout cell line (e.g., HeLa, HEK293) |
| What is the effect of a point mutation in IL6R on binding affinity? | IL6R point-mutant knock-in cell line |
| Can a tagged IL6R be used to track receptor trafficking? | IL6R-GFP knock-in cell line |
| Does overexpression of sIL-6R enhance trans-signaling? | sIL-6R overexpression cell model |
| What genes are regulated by IL-6/STAT3? | STAT3 knockout or knockdown followed by RNA-seq |
| Can CRISPR library screening identify modifiers of IL-6 signaling? | Genome-wide CRISPR knockout library in IL-6-responsive cells |
How to Study the interleukin-6 receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Characterizing IL-6/IL-6R interaction |
| Western blot | Phosphorylation of STAT3 and JAKs | Assessing pathway activation |
| Luciferase reporter assay | STAT3 transcriptional activity | Screening for inhibitors or activators |
| CRISPR knockout screening | Gene essentiality for IL-6 signaling | Identifying novel regulators |
| ELISA | Soluble IL-6R and IL-6 levels | Clinical biomarker measurement |
| Cryo-EM | 3D structure of receptor complex | Understanding binding interfaces |
| Flow cytometry | Cell surface IL-6R expression | Characterizing cell lines and patient samples |
| RNA-seq | Transcriptional changes upon IL-6 stimulation | Mapping downstream gene networks |
Binding Assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) measure the affinity and kinetics of IL-6 binding to IL-6R. ELISA-based assays can quantify soluble IL-6R levels in biological samples.
Signaling Pathway Analysis
Western blotting for phosphorylated STAT3 and JAKs is standard to assess IL-6R activation. Luciferase reporter assays driven by STAT3 response elements quantify transcriptional activity.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that modulate IL-6R binding and downstream signaling, revealing novel regulators. Pooled screens with IL-6-induced reporter expression enable high-throughput discovery.
Structural Biology
Cryo-EM and X-ray crystallography have elucidated the structure of the IL-6/IL-6R/gp130 complex, providing insights into binding interfaces and guiding drug design.
How CRISPR Can Be Used to Study GO:0005138 interleukin-6 receptor binding
Knockout
CRISPR-Cas9 knockout of IL6R, IL6, or IL6ST abolishes IL-6 receptor binding and downstream signaling, providing a clean background to study specific contributions. Knockout cell lines are valuable for drug screening and validating on-target effects.
Point Mutation
Introducing point mutations in IL6R (e.g., in the cytokine-binding domain) via CRISPR base editing or HDR allows precise dissection of binding residues and their impact on affinity and signaling. Such models mimic patient-derived mutations.
Knock-in
Knock-in of tagged IL6R (e.g., GFP or HA) enables live-cell imaging and proteomic analysis of receptor complexes. Knock-in of disease-associated variants (e.g., IL6R Asp358Ala) helps evaluate their functional consequences.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of IL6, IL6R, or sIL-6R can amplify signaling for biochemical studies and drug screening. Overexpression models are useful for studying trans-signaling and cytokine release.
How EDITGENE Supports interleukin-6 receptor binding Research
Researchers studying interleukin-6 receptor binding-related genes often need to determine whether a candidate gene is causally involved in signaling, inflammation, or disease. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for interleukin-6 receptor binding research.
Frequently Asked Questions About interleukin-6 receptor binding
What is interleukin-6 receptor binding?
Interleukin-6 receptor binding (GO:0005138) is the molecular function of a ligand, primarily interleukin-6 (IL-6), binding to the interleukin-6 receptor (IL-6R), initiating signaling cascades.
What genes are involved in interleukin-6 receptor binding?
Key genes include IL6 (ligand), IL6R (receptor), IL6ST (gp130 co-receptor), JAK1, JAK2, and STAT3 (downstream effectors).
What diseases are associated with interleukin-6 receptor binding?
Dysregulation is linked to rheumatoid arthritis, cytokine release syndrome, COVID-19, and cancers such as multiple myeloma.
How is interleukin-6 receptor binding studied?
Common methods include surface plasmon resonance, Western blot for STAT3 phosphorylation, CRISPR knockout screens, and structural biology techniques like cryo-EM.
What is the role of soluble IL-6R in binding?
Soluble IL-6R (sIL-6R) can bind IL-6 and stimulate cells expressing only gp130, a process called trans-signaling, which expands IL-6 responsiveness.
Can CRISPR be used to study interleukin-6 receptor binding?
Yes, CRISPR knockout of IL6R or IL6 abolishes binding, while knock-in of tagged or mutant receptors enables precise functional studies.
What drugs target interleukin-6 receptor binding?
Tocilizumab and sarilumab are monoclonal antibodies that block IL-6R binding and are approved for rheumatoid arthritis and COVID-19.
What is the difference between classic and trans-signaling?
Classic signaling occurs via membrane-bound IL-6R on target cells, while trans-signaling involves soluble IL-6R/IL-6 complexes activating cells that only express gp130.
How does interleukin-6 receptor binding activate STAT3?
Binding induces gp130 dimerization, activating JAKs that phosphorylate STAT3, which then dimerizes and translocates to the nucleus to regulate gene expression.
What cell models are available for IL-6 receptor binding research?
EDITGENE offers IL6R knockout, point-mutant, tagged knock-in, and overexpression cell lines, as well as CRISPR library screening services.
Conclusion
Interleukin-6 receptor binding (GO:0005138) is a fundamental molecular function that initiates a signaling cascade critical for immune regulation and inflammation. Its dysregulation underlies numerous diseases, making it a prime therapeutic target. Advances in CRISPR-based models and structural biology continue to unravel the intricacies of this binding event, offering new avenues for drug discovery and personalized medicine.
References
- 1. Rose-John S et al.. 2023. Targeting IL-6 trans-signalling: past, present and future prospects.. Nat Rev Immunol 23(10):666-681 PMID: 37069261
- 2. Scheller J et al.. 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6.. Biochim Biophys Acta 1813(5):878-88 PMID: 21296109
- 3. Seibel C et al.. 2024. Synthetic trimeric interleukin-6 receptor complexes with a STAT3 phosphorylation dominated activation profile.. Cytokine 184:156766 PMID: 39348731
- 4. Angriman F et al.. 2021. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.. Lancet Respir Med 9(6):655-664 PMID: 33930329
- 5. Kishimoto T. 1992. Interleukin-6 and its receptor in autoimmunity.. J Autoimmun 5 Suppl A:123-32 PMID: 1380241
- 6. Meyer C et al.. 2014. Stabilized Interleukin-6 receptor binding RNA aptamers.. RNA Biol 11(1):57-65 PMID: 24440854
- 7. Rose-John S. 2017. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.. Clin Pharmacol Ther 102(4):591-598 PMID: 28675418
- 8. Rose-John S. 2015. The soluble interleukin-6 receptor and related proteins.. Best Pract Res Clin Endocrinol Metab 29(5):787-97 PMID: 26522462
